Oragenics, Inc. (OGEN) - Form 8-K Summary
Business Context and Reporting Period
Oragenics, Inc. filed this Current Report on Form 8-K on December 19, 2022. The Company is incorporated in Florida and its common stock trades on the NYSE American under the symbol "OGEN". This filing addresses a regulatory notice regarding the Company's continued listing status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial data point disclosed is the stock price performance triggering the listing deficiency: the Company's shares have traded at a 30-trading-day average price of less than $0.20 per share for a substantial period.
Material Changes and Listing Deficiency
On December 19, 2022, the Company received a written notice from the NYSE American indicating non-compliance with Section 1003(f)(v) of the NYSE American Company Guide due to the low share price. The notice does not result in immediate delisting, and trading will continue under the symbol "OGEN".
- Deficiency: Failure to maintain a minimum bid price of $0.20 per share.
- Compliance Deadline: The Company must demonstrate sustained price improvement or effect a reverse stock split by June 19, 2023.
- Extension Possibility: The cure period could potentially be extended to the Company's next annual meeting of shareholders in 2023.
Outlook, Risks, and Management Commentary
Management stated that the Company intends to regain compliance by undertaking measures in the best interests of the Company and its shareholders. The Company is actively engaged in discussions with the NYSE American and developing plans to cure the deficiency. The receipt of the notice does not affect the Company's business operations or SEC reporting requirements.
The filing supplements risk factors to highlight the consequences of potential delisting, including:
- Limited availability of market quotations and reduced liquidity.
- Classification as a "penny stock," subjecting brokers to more stringent rules.
- Reduced news and analyst coverage.
- Decreased ability to issue additional securities or obtain financing.
- Loss of "covered securities" status, potentially subjecting the Company to state-level regulation.
Investor Verification Checklist
- Verify the current 30-day average trading price of OGEN stock to assess the gap from the $0.20 threshold.
- Monitor for announcements regarding a proposed reverse stock split or other capital structure changes.
- Review the Company's cash position in recent 10-Q or 10-K filings to determine if it has sufficient liquidity to fund operations if delisting occurs.
- Check for any subsequent correspondence with the NYSE American regarding the extension of the cure period.